Details

Autor(en) / Beteiligte

• Zost, Seth J
• Gilchuk, Pavlo
• Chen, Rita E
• Case, James Brett
• Reidy, Joseph X
• Trivette, Andrew
• Nargi, Rachel S
• Sutton, Rachel E
• Suryadevara, Naveenchandra
• Chen, Elaine C
• Binshtein, Elad
• Shrihari, Swathi
• Ostrowski, Mario
• Chu, Helen Y
• Didier, Jonathan E
• MacRenaris, Keith W
• Jones, Taylor
• Day, Samuel
• Myers, Luke
• Eun-Hyung Lee, F
• Nguyen, Doan C
• Sanz, Ignacio
• Martinez, David R
• Rothlauf, Paul W
• Bloyet, Louis-Marie
• Whelan, Sean P J
• Baric, Ralph S
• Thackray, Larissa B
• Diamond, Michael S
• Carnahan, Robert H
• Crowe, Jr, James E

Titel

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Ist Teil von

• Nature medicine, 2020-09, Vol.26 (9), p.1422-1427

Ort / Verlag

United States: Nature Publishing Group

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date . In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms.